Table 1.
Clinical and laboratory characteristics of the subjects (n = 11) before and after rosiglitzone treatment for 90 d
| Variables | Before treatment (Visit 1) | After treatment (Visit 6) | P value |
|---|---|---|---|
| BMI, kg/m2 | 27.8 ± 2.7 | 28.2 ± 2.9 | 0.016 |
| Fat mass,% | 29.8 ± 4.6 | 30.6 ± 4.4 | 0.277 |
| Systolic blood pressure, mmHg | 150 ± 12 | 139 ± 6 | 0.0005 |
| Diastolic blood pressure, mmHg | 90 ± 9 | 88 ± 10 | 0.445 |
| Total cholesterol, mM | 4.4 ± 1.1 | 5.6 ± 1.8 | 0.013 |
| LDL cholesterol, mM | 2.3 ± 1.1 | 3.0 ± 1.6 | 0.230 |
| HDL cholesterol, mM | 1.3 ± 0.3 | 1.4 ± 0.5 | 0.465 |
| Triglycerides, mM | 1.6 ± 1.1 | 2.4 ± 1.6 | 0.028 |
| Free fatty acids, mM | 0.64 ± 0.19 | 0.56 ± 0.19 | 0.056 |
| HbA1c,% | 6.2 ± 1.4 | 6.0 ± 1.0 | 0.168 |
| Adiponectin, μg/mL | 6.3 ± 2.8 | 16.0 ± 6.6 | 0.0001 |
| Fasting plasma glucose, mM | 8.7 ± 2.4 | 7.4 ± 1.5 | 0.02 |
| Fasting plasma insulin, mU/L | 13.7 ± 8.4 | 11.7 ± 5.8 | 0.145 |
| QUICKI | 0.221 ± 0.031 | 0.234 ± 0.033 | 0.002 |
| C-reactive protein, mg/L | 6.3 ± 8.8 | 1.6 ± 0.6 | 0.11 |
Physical and serum parameters from patients (n = 11) before and after rosiglitazone treatment for 90 d were measured as described in the Materials and Methods. Data were analyzed by the two-tailed and paired Student t test. Abbreviation: BMI, body mass index, kg/m2; LDL, low density lipoproteins; HDL, high density lipoproteins; HbA1c, hemoglobin A1c; QUICKI, quantitative insulin sensitivity check index.